期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 60, 期 9, 页码 5600-5603出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00229-16
关键词
-
资金
- Astellas Pharma US (Astellas)
We evaluated the efficacy of isavuconazole against cryptococcal meningitis. Treatment with either oral isavuconazole (120 mg/kg and 240 mg/kg twice a day [BID]) or fluconazole as the positive control significantly improved survival in mice infected intracranially with either Cryptococcus neoformans USC1597 or H99 and significantly reduced brain fungal burdens for both isolates. Concentrations of isavuconazole in plasma and brain tissue also demonstrated that the greatest improvements in survival and fungal burden were associated with elevated exposures.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据